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Cancer is a leading cause of mortality worldwide, and life-
changing drugs and therapeutic regimens are urgently need-
ed. While natural products and synthetic molecules have
contributed to the management of different cancers, it is
known that their inherent cytotoxicity yields narrow ther-
apeutic windows. Hence, several potentially useful drugs have
been discontinued from development pipelines or seen
limited clinical application.[1]
Targeted therapies afford viable solutions to finally fulfill
Paul EhrlichQs century-old “magic bullet” promise. Newly
developed materials, nanotechnologies, and antibody–drug
conjugates (ADCs) have the potential to reshape the treat-
ment of aggressive and otherwise poorly manageable cancers.
Indeed, ADCs couple the specific recognition of tumor-
associated antigens by antibodies to the high cytotoxicity of
payloads to afford an active targeting construct. To date, four
ADCs have been approved for clinical use—Adcetris, Kad-
cyla, Besponsa, and Mylotarg—and more than 60 are under-
going clinical trials.[2] Despite this being a mature concept,
much can be improved in future ADCs. For example, tuned
linker technologies and advanced site-specific conjugation
chemistry can strongly influence the drug–antibody ratio,
solubility, pharmacokinetics, and ultimately ADC efficacy. To
that end, efforts have been made for the discovery of
reactions leading to stable and homogeneous ADCs.[3]
The development of cleavable linkers, and the engineer-
ing of releasing mechanisms for them, has been considered
essential for appropriate bioactivity of the payload in a disease
setting. While acid-labile hydrazone linkers have historical
importance, more recently, two releasing mechanisms have
been exploited, taking into account the fact that antibodies
are internalized once bound to the antigen followed by
lysosomal degradation: 1) a disulfide linkage is reduced in the
presence of biological thiols such as glutathione with sub-
sequent release of the payload and 2) a valine-citrulline linker
is cleaved by a protease (e.g. cathepsin B) to release the
payload (Figure 1). These conditionally stable moieties were
designed for intracellular delivery of the unmodified payload,
and selectively kill the cancer cell and its diseased neighbors
through the so-called bystander effect, without harming
healthy tissues. The natural product realm has been prolific
in providing viable payloads for ADC research. Still, their
modes of action remain limited. Typically, payloads are
peptidic and/or macrocyclic and act through interference
with either tubulin or DNA. However, emerging payload
classes now include camptothecin and pyrrolobenzodiaze-
pines. It is now also known that non-internalizing ADCs can
afford equally effective constructs for cancer therapy.[4]
Indeed the tumor microenvironment is also rich in payload-
releasing triggers that ought to be explored in depth.
Similarly, ADCs may be best employed for liquid tumors
where permeation of a rather bulky construct is not a limiting
factor.
Despite the payload release-by-design nature of ADCs,
undesired drug bleaching has been commonly observed,
resulting in untargeted drug delivery and toxicity. A leading
cause for such premature payload liberation stems from the
maleimide conjugation chemistry, since maleimides are prone
to retro-Michael additions.[5] Consequently, improving overall
ADC stability remains a topic of intense research.
Figure 1. Common linkers used in ADCs and their drug-release mech-
anisms.
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Recently,[6] researchers at Genentech have shown that
suppression of the protease cathepsin B through CRISPR-
Cas9 gene deletion or shRNA knockdown had no statistically
significant effect on the anticancer activity of monomethyl
auristatin E (MMAE) in ADCs featuring the cleavable
valine-citrulline linker (S-configured citrulline). The obser-
vation was reproducible in different cell lines with different
degrees of intracellular accumulation of the tool constructs. In
fact, mass spectrometry analyses suggested that other cysteine
cathepsins are able to cleave the abovementioned linker with
differing levels of efficiency.[6] This observation further
complements the recent finding that the valine-citrulline
linker is cleaved by carboxyesterase 1c, a key player in
extracellular cleavage of said linkers and promoter of reduced
ADC efficacy.[7] The result also supports functional redun-
dancy within the cathepsin protease family and overlapping
substrates that allow catalytic compensation whenever cath-
epsin B expression is either reduced or absent. Cathepsin S
appears to be particularly efficient in cleaving the valine-
citrulline linker.[6]
Contrary to current thinking in ADC research, a fully
stable construct featuring the non-cleavable valine-citrulline
(R-configured citrulline) linker counterpart resulted in sig-
nificant anticancer activity (IC50 value of 0.063 mg mL
@1 for
the parental KPL-4 cell line and 0.085 mgmL@1 for cells not
expressing cathepsin B). Although the valine-(R)-citrulline–
MMAE ADCs are only around 50% as potent as the S-
configured controls, their anticancer activity is still much
higher than anticipated.[6] What are then the underlying
mechanisms of MMAE release and action? The data clearly
show that lysosomal catabolism is robust in the sense that it
liberates bioactive metabolites, through multiple mechanisms,
from ADCs. Of note, the cysteine adduct of valine-(R)-
citrulline–MMAE could be identified as the major catabolite
from an ADC with a non-cleavable linker.[6] One must
wonder whether the strategy can be generally applicable? We
reason that ADCs with non-cleavable linkers may be useful
for internalizing antibodies. One can also envisage the
extrapolation of such constructs to afford antibody–antibiotic
conjugates. Otherwise there is no guarantee that the resulting
metabolites are the same as those originating inside the
lysosome and questions remain about their membrane
permeability (Figure 2).
Genentech has also built anti-HER2 ADCs carrying
pyrrolobenzodiazepine dimers attached via non-cleavable
alkyne, triazole, and piperazine moieties.[8] Iterative comput-
er-assisted drug design and synthesis efforts resulted in
entities that likely preserved the intended binding mode of
the dimer to the DNA minor groove. Subsequently, anti-
bodies were engineered with two cysteine residues to afford
a drug/antibody ratio of 2, the homogeneity of which was
confirmed by LC–MS. The constructs displayed varying
potencies across the model cell lines, with values in the low
ng mL@1 range. Most importantly, the constructs showed dose-
responsive efficacy (0.3–6 mgkg@1) in the HER-positive
Founder 5 mammary tumor transplant mouse model, which
correlated with the in vitro assay data. Overall, the results
support the validity of such ADCs as cancer therapeutics.
Moreover, they raise question marks over which variables are
indeed relevant for optimization for the purpose of improving
the cell-killing activity of ADCs. While linkers play an
important role in modulating the physicochemical/pharma-
cokinetic properties of the constructs, it is now clearer than
ever that cellular bioactivity is more connected to the
employed antibodies and payloads.
Linking drugs directly to antibodies holds great promise
and can be applicable to ligands of diverse target families. For
example, crizotinib, a kinase inhibitor, was directly conjugat-
ed through aza-Michael ligation to dehydroalanine. The
construct showed a 10-fold activity improvement when
compared to the small molecule against SKBR3 breast cancer
cells.[9]
It is however important to retain a healthy skepticism. For
example, payloads should be sufficiently potent to ensure
drug-target saturation and
avoid undesirable antibody
loading that could lead to
aggregation. Also, what is
the magnitude of the by-
stander effect for linkerless
ADCs? With some pharma-
ceutical companies opting
out of the ADC field, it is
clear that numerous chal-
lenges and drawbacks might
be expected. Nonetheless,
we foresee that linkerless
ADCs will be explored
more frequently in the fu-
ture to exploit payloads with
differentiated modes of ac-
tion. Taking into account the
recent track record, the re-
sulting constructs could pro-
vide therapeutic alternatives
that are at least as effective
Figure 2. ADCs with non-cleavable linker and release mechanism of the payloads. Payloads for which the
strategy has been validated are depicted. Image compiled by Claudia Flandoli.
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as the cleavable counterparts but with minimal manipulation
and improved stability.
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